News | January 12, 2022
Covaxin booster neutralises Omicron and Delta variants: Study
The study will be published on the pre-print server, medRXiv, shortly
The study will be published on the pre-print server, medRXiv, shortly
In addition to its favourable activity profile, IBIO123 is formulated for administration by inhalation providing an efficient, rapid and non-invasive delivery method into the lungs via the respiratory tract
The long-term partnership aims to make fermentation-based biotin available for the full range of relevant applications as a sustainable, non-chemical, European-sourced alternative
Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with Beam’s leadership in base editing and mRNA/LNP delivery technologies
The company’s platform technology works like a compression algorithm for molecular testing and has applications in healthcare, pharmaceuticals, agriculture, animal husbandry, food safety, synthetic biology, and molecular biology research
TATA MD’s OmiSure is the only test approved by the ICMR for RT-PCR detection of the Omicron variant
Topline results from the randomized EMPATHY Part A study in acute Covid-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction over eight days
Simulated Moving Bed (SMB) technology is a highly engineered process for implementing chromatographic separation
Novavax' vaccine has received authorizations of the vaccine in over 170 countries
Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties
Subscribe To Our Newsletter & Stay Updated
